Uremic retention solute indoxyl sulfate level is associated with prolonged QTc interval in early CKD patients

Wei-Hua Tang1, Chao-Ping Wang2, Fu-Mei Chung2

  • 1Graduate Institute of Medicine, Collage of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Plos One
|April 21, 2015
PubMed

Insights

High indoxyl sulfate (IS) levels in chronic kidney disease (CKD) patients are linked to prolonged QTc intervals. IS disrupts potassium channels, potentially causing dangerous heart arrhythmias in CKD.

Area of Science:

  • Nephrology
  • Cardiology
  • Molecular Biology

Background:

  • Chronic kidney disease (CKD) is associated with high rates of mortality and sudden cardiac death.
  • Indoxyl sulfate (IS), a protein-bound uremic toxin, is independently linked to cardiovascular disease in CKD patients.
  • The precise mechanisms by which IS contributes to cardiovascular complications remain unclear.

Purpose of the Study:

  • To investigate the relationship between IS and cardiac electrocardiographic parameters in early CKD.
  • To elucidate the in vitro and in silico arrhythmogenic effects of IS on cardiomyocytes.

Main Methods:

  • Prospective observational study of 100 early CKD patients.
  • In vitro electrophysiological studies on cardiomyocytes.
  • Mathematical computer simulations (ORd model) to model cardiac electrophysiology.

Main Results:

  • Higher IS levels correlated with prolonged QTc intervals in CKD patients.
  • IS significantly decreased the delayed rectifier potassium current (IK) in a dose-dependent manner.
  • IS modulates IK current by regulating Kv 2.1 phosphorylation, prolonging action potential duration and inducing early afterdepolarizations in silico.

Conclusions:

  • Serum IS levels are independently associated with prolonged QTc intervals in early CKD.
  • IS downregulates IK channel activity, increasing cardiomyocyte action potential duration and QTc interval.
  • These findings suggest IS contributes to arrhythmogenesis in CKD patients.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.0K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
518
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
332
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.3K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.0K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
390